Engineered phagocytic receptor compositions and methods of use thereof

A pharmaceutical composition comprising:

• (a) myeloid cells from a human subject comprising a recombinant polynucleic acid, wherein the myeloid cells are CD14+ and CD16−, and wherein the recombinant polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:
• (i) an extracellular domain comprising a CD5 binding domain, wherein the CD5 binding domain comprises an scFv comprising a variable heavy chain (VH) sequence with SEQ ID NO:
• 1 and a variable light chain (VL) sequence with SEQ ID NO:
• 2,
• (ii) a CD8 transmembrane domain operatively linked to the extracellular domain;
• and
• (iii) an intracellular domain comprising at least two intracellular signaling domains, wherein the at least two intracellular signaling domains comprise:
• (A) a first intracellular signaling domain derived from FcγR or FcεR, and
• (B) a second intracellular signaling domain comprising a PI3K recruitment domain;
• and
• (b) a pharmaceutically acceptable carrier;
• wherein the myeloid cells express the CFP and exhibit at least a 1.1 fold increase in phagocytosis of a target cell expressing CD5;
• and
• wherein the pharmaceutical composition comprises an effective amount of the myeloid cells to inhibit growth of a solid tumor when administered to a human subject with the solid tumor.